| Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma J Gao, N Navai, O Alhalabi, A Siefker-Radtke, MT Campbell, RS Tidwell, ... Nature medicine 26 (12), 1845-1851, 2020 | 217 | 2020 |
| Factor XII and uPAR upregulate neutrophil functions to influence wound healing EX Stavrou, C Fang, KL Bane, AT Long, C Naudin, E Kucukal, A Gandhi, ... The Journal of clinical investigation 128 (3), 944-959, 2018 | 128 | 2018 |
| 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, ... Nature communications 12 (1), 5606, 2021 | 97 | 2021 |
| Reduced thrombosis in Klkb1−/− mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor EX Stavrou, C Fang, A Merkulova, O Alhalabi, N Grobe, S Antoniak, ... Blood, The Journal of the American Society of Hematology 125 (4), 710-719, 2015 | 94 | 2015 |
| Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016 AO Elmehrath, AM Afifi, MJ Al-Husseini, AM Saad, N Wilson, KS Shohdy, ... JAMA Network Open 4 (8), e2119568-e2119568, 2021 | 62 | 2021 |
| Prognostic factors in patients with metastatic breast cancer with bone‐only metastases A Parkes, CL Warneke, K Clifton, A Al‐Awadhi, O Oke, RC Pestana, ... The oncologist 23 (11), 1282-1288, 2018 | 54 | 2018 |
| Immunotherapy for melanoma AA Albittar, O Alhalabi, IC Glitza Oliva Immunotherapy, 51-68, 2020 | 53 | 2020 |
| Managing cancer care during the COVID-19 pandemic and beyond O Alhalabi, V Subbiah Trends in cancer 6 (7), 533-535, 2020 | 30 | 2020 |
| MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers O Alhalabi, J Chen, Y Zhang, Y Lu, Q Wang, S Ramachandran, ... Nature communications 13 (1), 1797, 2022 | 29 | 2022 |
| A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease HR Gittleman, A Merkulova, O Alhalabi, EX Stavrou, ML Veigl, ... Frontiers in Medicine 3, 17, 2016 | 27 | 2016 |
| Impact of BRCA mutation status on survival of women with triple-negative breast cancer S Yadav, R Ladkany, D Yadav, O Alhalabi, S Khaddam, D Isaac, ... Clinical breast cancer 18 (5), e1229-e1235, 2018 | 24 | 2018 |
| Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer O Alhalabi, Y Zhu, A Hamza, W Qiao, Y Lin, RM Wang, AY Shah, ... European Urology Oncology 6 (2), 228-232, 2023 | 17 | 2023 |
| Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas J Thouvenin, O Alhalabi, M Carlo, L Carril-Ajuria, L Hirsch, ... The Oncologist 27 (12), 1041-1047, 2022 | 15 | 2022 |
| Testing for COVID-19 in patients with cancer O Alhalabi, S Iyer, V Subbiah EClinicalMedicine 23, 2020 | 15 | 2020 |
| Targeting advanced urothelial carcinoma-developing strategies O Alhalabi, H Rafei, A Shah, A Siefker-Radtke, M Campbell, J Gao Current opinion in oncology 31 (3), 207-215, 2019 | 13 | 2019 |
| Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. O Alhalabi, AY Shah, EA Lemke, J Gao Oncology (08909091) 33 (1), 2019 | 12 | 2019 |
| Immune checkpoint therapy combinations in adult advanced MiT family translocation renal cell carcinomas O Alhalabi, J Thouvenin, S Négrier, YA Vano, L Campedel, E Hasanov, ... The Oncologist 28 (5), 433-439, 2023 | 9 | 2023 |
| Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: current knowledge and future directions J Thouvenin, N Martínez Chanzá, O Alhalabi, H Lang, NM Tannir, ... Cancers 13 (17), 4341, 2021 | 9 | 2021 |
| The evolving treatment landscape of advanced urothelial carcinoma AY Andreev-Drakhlin, G Egoryan, AY Shah, P Msaouel, O Alhalabi, J Gao Current opinion in oncology 33 (3), 221-230, 2021 | 9 | 2021 |
| Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology O Alhalabi, JA Karam, NM Tannir Current opinion in urology 29 (5), 521-525, 2019 | 9 | 2019 |
Pavlos Msaouel, MD, PhDAssistant Professor, MD Anderson Cancer CenterVerified email at mdanderson.org
